FDA approves Aurobindo’s generic Invanz injection
The Food and Drug Administration has approved Aurobindo Pharma’s generic Invanz injection (ertapenem injection, 1 g/vial). The drug is indicated to treat moderate-to-severe infections caused by susceptible bacteria and to prevent surgical site infection following elective colorectal surgery.
Aurobindo said it expects to launch the generic iInvanz injection in July. The product will launch into a market with annual sales of $387 million for the 12 months ended April 2018, according to IQVIA data. With this approval, Aurobindo has racked up 371 generic approvals.
Aurobindo said it expects to launch the generic iInvanz injection in July. The product will launch into a market with annual sales of $387 million for the 12 months ended April 2018, according to IQVIA data. With this approval, Aurobindo has racked up 371 generic approvals.